top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Radiation Dose Management Market: Business Overview and Global Development Trends

0 votes
5 views

Transparency Market Research has published a new report titled, “Radiation Dose Management Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global radiation dose management market was valued at US$ 143.2 Mn in 2017 and is projected to expand at a CAGR of 26.7% from 2018 to 2026 to reach US$ 1,361.5 Mn in 2026. Rise in prevalence of chronic diseases such as cardiovascular and cancer, increase in geriatric population, growing safety concerns and improving quality of patient care, surge in demand for medical imaging, emerging economies in Asia Pacific, Latin America, and Middle East & Africa, and technological advancements are expected to propel the global radiation dose management market during the forecast period.

Planning To Lay Down Future Strategy? Request Brochure Of Radiation Dose Management Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25394

Increase in Usage of Integrated Software Systems

Owing to increasing number of chronic diseases such as cardiovascular, cancer and increasing demand for medical imaging in diagnosis of these diseases, compiled with the prime intent of updating the stakeholders with the unavoidable market parameters through a graphical illustration and in-depth analysis of each segment considered within the study scope.

Increase in government funding to setup high quality health care infrastructure is anticipated to propel the market during the forecast period. Rise in usage of integrated software in medical imaging devices which enables the interlinking of various images and databases is expected to augment the market. Surge in funding from government and private sector for oncology treatment in terms of reimbursement is likely to contribute to the growth of the market. Increase in government programs to prevent high radiation dose is projected to propel the market during the forecast period.

Computed Tomography Held Major Market Share

In terms of modality, the computed tomography segment accounted for major market share in 2017. Growth of the segment is attributed to increase in number of diseases and requirement of CT scan for diagnosis of these diseases. The radiography and mammography segment is likely to be driven by increase in application in the diagnosis and treatment analysis of cancer at various stages and in the diagnosis of orthopedic, dental, and chronic conditions such as pneumonia.

To Obtain All-Inclusive Information On Forecast Analysis Of Radiation Dose Management Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=25394

Rise in Cancer Cases across the Globe

In terms of application, the oncology segment held the major market share in 2017 and the trend is projected to continue during the forecast period. Growth of the segment is attributed to increasing number of cancer cases. Moreover, according to WHO report, cancer is expected to account for 70% of global deaths in the next two decades. Surge in the number of orthopedic cases and usage of different imaging techniques during the course of the treatment are likely to fuel the growth of the segment.

Hospitals Segment Dominates Market

The hospitals segment accounted for the largest share of the market in 2017. The predominance of the market share of the hospitals segments over other segments  is because, hospital pharmacy is mostly preferred by patients owing to the fact that all types of diagnosis is widely available in hospitals as compared to others. Additionally, increasing incidence of chronic diseases such as cancer, cardiovascular diseases are well treated in the hospitals. Initiatives by government bodies to develop health care infrastructure and to attract women are projected to propel the hospitals segment. Ambulatory centers contribute less for the growth radiation dose monitoring market, due to high installment cost of medical devices which is a restraining factor for the clinics to provide this facility

Asia Pacific to Witness Exponential Growth

Asia Pacific is projected to be the fastest growing market for radiation dose management during the forecast period owing to increase in incidence of chronic diseases and rise in awareness about diagnosis, especially in China and Japan. Moreover, surge in investments to enhance the adoption of health care IT technologies in countries such as India and Australia drives demand for radiation dose management solutions.

North America held major share of the global radiation dose management market in 2017, attributed to well-established health care infrastructure, presence of key players, and favorable reimbursement policy. Moreover, incidence of cancer, cardiovascular diseases, and neurological disorders is increasing in North America which require imaging tests for diagnosis. Emerging markets such as Latin America and Middle East & Africa are also likely to witness strong growth due to the emergence of key players in these regions and increase in incidence of diseases.

Afga-Gevaert N.V., Bayer Healthcare AG, Koninklijke Philips N.V., GE Healthcare, Thermo Fisher Scientific, and Fujifilm Holdings Corporation to Lead the Market

Key players operating in the global radiation dose management market are Landauer, Inc., Spectra AB, Agfa-Gevaert N.V., INFINITT Healthcare Co. Ltd., Bayer AG, PACSHealth, LLC, Koninklijke Philips N.V., GE Healthcare, Thermo Fisher Scientific, Fujifilm Holdings Corporation, and QAELUM NV.

posted Feb 11 by Rohini Chaudhari

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

Transparency Market Research (TMR) has published a new report titled,“Radiation Therapy Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global radiation therapy market was valued at US$ 5,445.3 Mn in 2017 and is projected to expand at a CAGR of 5.2% from 2018 to 2026. Increase in incidence and prevalence of cancer, technological advancements, rise in health care expenditure, surge in product approvals, and rise in demand for non-invasive treatment procedures are anticipated to augment the global market from 2018 to 2026.

Increase in Patient Population to Propel Market

Increase in incidence and prevalence of cancer across the globe is projected to drive the global radiation therapy market during the forecast period, as radiation therapy is used in nearly 50% of all cancer treatments. Rise in the number of cancer patients across the world is anticipated to propel demand for therapeutics. According to the American Institute of Cancer Research, around 18 million cancer cases were diagnosed globally in 2018 and head & neck cancer accounted for about 4% of all cancers in the U.S. in 2017. Moreover, an estimated 65,000 individuals will develop head & neck cancer in the near future.

Technological Advancements

Increase in demand for highly efficient radiation therapy systems for cancer treatment and new product approvals are projected to augment the global radiation therapy market during the forecast period. The global market has witnessed an increase in new product approvals in the past few years. This is anticipated to propel the global market from 2018 to 2026. For instance, in February 2019, ViewRay, Inc. received 510(k) clearance from the U.S. FDA to market new soft tissue visualization capabilities for the MRIdian system. The system is expected to help clinicians in the assessment and prediction of radiation therapy.

Request PDF Sample of Radiation Therapy Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=36080

High Cost of Treatment to Restrain Market

Radiation therapy in general has high costs linked to it due to the use of sophisticated equipment and machinery. The total cost of treatment depends upon the number of sessions, type of radiation, and patient’s health coverage. According to estimates, the cost for a radiation therapy course for treating breast cancer is approximately US$ 8,000, and around US$ 18,000 for prostate cancer.

Asia Pacific Market to Grow at a Rapid Pace

In terms of revenue, the radiation therapy market in Asia Pacific is projected to expand at a high CAGR during the forecast period. Rapidly increasing patient population in the region and rise in product launches are anticipated to boost demand for radiation therapy systems, which in turn is expected to drive the market from 2018 to 2026. Increase in government expenditure in the health care segment is likely to fuel the growth of the radiation therapy market in Asia Pacific during the forecast period. According to the Union Budget of India for 2017–2018, the total health care expenditure was increased from 1.97% to 2.27% of the total budget.

Buy Now “Radiation Therapy Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=36080&ltype=S

Varian Medical Systems and Elekta AB Company to Lead Market

The report also provides profiles of leading players operating in the global radiation therapy market. These include Varian Medical Systems, Elekta AB, IBA Radiopharma Solutions, Accuray Incorporated, Isoray, Inc., Mevion Medical Systems, Hitachi, Ltd., ViewRay, Inc., and Panacea Medical Technologies Pvt. Ltd. Increase in mergers & acquisitions, strategic collaborations, and new product launches are expected to drive the global market during the forecast period. For instance, in November 2017, Varian Medical Systems opened a new facility in Jundiai, Brazil, to increase access to advanced radiotherapy treatment in the country and across Latin America.

0 votes

The global pain management devices market features an increasingly competitive landscape marked by rising level of competition among its players. A plethora of players in the market are vying for higher stakes. To this end, they are focusing on unveiling various types of pain management devices with novel technologies in order to reap competitive benefits. Several prominent players have been engaged in expanding their portfolio to consolidate their shares in the global pain management devices market. Rising investments on research and development activities is likely to up the intensity of competition in the pain management devices market in the coming years.

Some of the top players operating in the global pain management devices market are Bio-Medical Research (BMR) Ltd., Halyard Health, Stryker Corp, Baxter International Inc., and Boston Scientific Corp.

The global pain management devices market stood US$3.75 billion in 2016 and is projected to touch a valuation of US$6.28 billion by the end of 2023. This represents a CAGR of 7.6% during the forecast period of 2015–2023.

Request Sample @ 

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1143

Among the various types of products, neurostimulation devices held the leading share in 2015 and is likely to hold its sway throughout the assessment period. The prevalence of high-impact chronic pain conditions such as those by musculoskeletal is expected to bolster the uptake in the next few years.

Of the key regional markets for pain management devices, North America has been consistently garnering substantial shares over past few years. The regional market for pain management device is anticipated to continue holding prominent shares in the near future, as well. The growth is increasingly fueled by rising incidence sports-related injuries that need pain management devices.

Prevalence of Sports-Related Musculoskeletal Injuries offers Robust Boost

The rising demand for better management technologies among patient populations world over is a key factor driving the pain management devices market. Globally rising opioid epidemic has offered an attractive impetus to the demand for pain management technologies. Rising elderly populations, especially in developing and developed nations, has contributed to the prevalence of chronic pain. This is a notable trend bolstering the demand for pain management devices. In numerous countries, the rising incidence of sports and recreation-related injuries leading to hospitalization is bolstering the demand for pain management devices. In particular, the demand is increasingly receiving solid boost from the prevalence of sports-related musculoskeletal injuries in developed countries.

Want to know the obstructions to your company’s growth in future? Request a Pree Book @ 

https://www.transparencymarketresearch.com/checkout.php?rep_id=1143&ltype=S

The global pain management devices market is likely to get attractive impetus from several government initiatives and favorable regulatory landscape. In developed nations, reimbursements for spinal cord stimulation devices for patient populations have been fueling the market’s growth in developed countries.

Demand for Better Pain Management Devices for Neuropathic Pain creates Substantial Prospects

The advent of novel pain management devices has created new, exciting avenues in the global market. Increasing pace of commercialization of such devices in recent years has catalyzed rapid market’s expansion.

The global pain management devices market is likely to witness setbacks on account of low level of patient awareness and the high cost of these devices. Moreover, potential side-effects with certain pain management devices have dampened the uptake. The risk of side effects of skin erosion and surgical site infection associated with neurostimulation implants is a case in point.

Nevertheless, the rising incidence of neuropathic pain world over is making room for several lucrative avenues for medical device manufacturers. They are expanding their pipeline of products. Moreover, the rising awareness about the ill effects of prescription pain killers kindles patients’ interest in technologically-advanced pain management devices.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Pain Management Devices Market (Product Type – Electrical Stimulation Devices, Radiofrequency Ablation Devices, Analgesic Infusion Pumps, and Neurostimulation Devices; Application – Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, and Musculoskeletal Pain

0 votes

Transparency Market Research has published a new report titled, “Radiation Dose Management Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global radiation dose management marketwas valued at US$ 143.2 Mn in 2017 and is projected to expand at a CAGR of 26.7% from 2018 to 2026 to reach US$ 1,361.5 Mn in 2026. Rise in prevalence of chronic diseases such as cardiovascular and cancer, increase in geriatric population, growing safety concerns and improving quality of patient care, surge in demand for medical imaging, emerging economies in Asia Pacific, Latin America, and Middle East & Africa, and technological advancements are expected to propel the global radiation dose management market during the forecast period.

Increase in Usage of Integrated Software Systems

Owing to increasing number of chronic diseases such as cardiovascular, cancer and increasing demand for medical imaging in diagnosis of these diseases, compiled with the prime intent of updating the stakeholders with the unavoidable market parameters through a graphical illustration and in-depth analysis of each segment considered within the study scope. Increase in government funding to setup high quality health care infrastructure is anticipated to propel the market during the forecast period.

Request PDF Sample of Radiation Dose Management Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=25394

Rise in usage of integrated software in medical imaging devices which enables the interlinking of various images and databases is expected to augment the market. Surge in funding from government and private sector for oncology treatment in terms of reimbursement is likely to contribute to the growth of the market. Increase in government programs to prevent high radiation dose is projected to propel the market during the forecast period.

Computed Tomography Held Major Market Share

In terms of modality, the computed tomography segment accounted for major market share in 2017. Growth of the segment is attributed to increase in number of diseases and requirement of CT scan for diagnosis of these diseases. The radiography and mammography segment is likely to be driven by increase in application in the diagnosis and treatment analysis of cancer at various stages and in the diagnosis of orthopedic, dental, and chronic conditions such as pneumonia.

Rise in Cancer Cases across the Globe

In terms of application, the oncology segment held the major market share in 2017 and the trend is projected to continue during the forecast period. Growth of the segment is attributed to increasing number of cancer cases. Moreover, according to WHO report, cancer is expected to account for 70% of global deaths in the next two decades. Surge in the number of orthopedic cases and usage of different imaging techniques during the course of the treatment are likely to fuel the growth of the segment.

Enquiry for Discount on “Radiation Dose Management Market ” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=25394

Hospitals Segment Dominates Market

The hospitals segment accounted for the largest share of the market in 2017. The predominance of the market share of the hospitals segments over other segments  is because, hospital pharmacy is mostly preferred by patients owing to the fact that all types of diagnosis is widely available in hospitals as compared to others. Additionally, increasing incidence of chronic diseases such as cancer, cardiovascular diseases are well treated in the hospitals. Initiatives by government bodies to develop health care infrastructure and to attract women are projected to propel the hospitals segment. Ambulatory centers contribute less for the growth radiation dose monitoring market, due to high installment cost of medical devices which is a restraining factor for the clinics to provide this facility

Asia Pacific to Witness Exponential Growth

Asia Pacific is projected to be the fastest growing market for radiation dose management during the forecast period owing to increase in incidence of chronic diseases and rise in awareness about diagnosis, especially in China and Japan. Moreover, surge in investments to enhance the adoption of health care IT technologies in countries such as India and Australia drives demand for radiation dose management solutions. North America held major share of the global radiation dose management market in 2017, attributed to well-established health care infrastructure, presence of key players, and favorable reimbursement policy. Moreover, incidence of cancer, cardiovascular diseases, and neurological disorders is increasing in North America which require imaging tests for diagnosis. Emerging markets such as Latin America and Middle East & Africa are also likely to witness strong growth due to the emergence of key players in these regions and increase in incidence of diseases.

Afga-Gevaert N.V., Bayer Healthcare AG, Koninklijke Philips N.V., GE Healthcare, Thermo Fisher Scientific, and Fujifilm Holdings Corporation to Lead the Market

Key players operating in the global radiation dose management market are Landauer, Inc., Spectra AB, Agfa-Gevaert N.V., INFINITT Healthcare Co. Ltd., Bayer AG, PACSHealth, LLC, Koninklijke Philips N.V., GE Healthcare, Thermo Fisher Scientific, Fujifilm Holdings Corporation, and QAELUM NV.

0 votes

Constant entry of biotechnology and pharmaceutical companies in the global cell based assays market accounts for the prevailing forces of fragmentation, notes Transparency Market Research (TMR). These companies benefit increasingly from substantial financial clout they have, which helps them leverage the forces of competition in their favor, finds TMR.

Some of the key players vying for sizeable stakes in the global cell based assays market are Danaher Corporation, Thermo fisher Scientific Inc., Marin Biologic Laboratories, Essen BioScience Inc., Enzo Life Sciences, Inc., and QGel SA.

The global cell-based assays market was worth approximately US$1.36 billion in 2017. During 2017–2022, the market is projected to expand at CAGR of 7.7% and reach a valuation of US$1.97 billion by 2022 end.

Based on end user, the biotechnology and pharmaceutical segment holds the sway in the global cell based assays market. The segment will continue to hold a major share globally in the coming few years as well. The growth is propelled by rapid application of cell-based assays in drug discovery world over.

Planning To Lay Down Future Strategy? Request Brochure Of Cell Based Assays Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=846

Regionally, North America accounted for the major share in the global cell-based assays market in 2017. The regional market will clock a CAGR of 8.2% during 2017–2022. The growth is fueled by substantial volumes of investments being poured into research and development activities in the region.

Widespread Application in Drug Discovery Applications propels Growth

The global cell based assays market is driven increasingly by the widespread application of the methodologies in drug discovery applications in drug making. The applications are notably bolstered by rapidly rising number of drugs for chronic diseases in various regions across the world. The prevalence of cardiovascular diseases and diabetes is also fueling the demand for cell-based assays.

There contours of the global cell based assays market is shaped by the rising demand for more efficacious drugs for various life-threatening diseases. The growing role of cell-based assays in drug discovery for cancer is a case in point.

Growing role of cell-based assays in accelerating time-to-market of drugs by pharmaceutical and biotech companies is a key trend aiding in the rapid stride of the global cell based assays market. These assays occupy notable a pivotal role in reducing the instances of late-stage drug failures. Moreover, rising demand for cell-based assays methodologies in investigational new drugs is a key trend boosting the market. Furthermore, growing number of in vitro drug studies based on cell-based assays is fueling the market’s growth.

To Obtain All-Inclusive Information On Forecast Analysis Of Cell Based Assays Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=846

High Cost of Assay Instruments and Unfavorable Regulatory Framework hampers Prospects

However, the steady growth of the global cell-based assays market is hindered by the high cost of assay instruments and lack of suitable regulatory framework for the use of reagents. Nevertheless, the rising worldwide demand for novel drugs and treatments is also likely to create new, exciting avenues in the market. The rising use of cell-based assays in various ultra-high throughput screening also paves way for lucrative opportunities for pharmaceutical and biotech companies. Furthermore, exciting strides witnessed in synthetic biology in recent years are also underpinning the growing prospects of the global cell-based assays market.

More Trending Reports by Transparency Market Research –

In-vitro Colorectal Cancer Screening Tests Market - 

https://www.globenewswire.com/news-release/2019/02/21/1739306/0/en/In-vitro-Colorectal-Cancer-Screening-Tests-Market-to-Hit-US-980-6-Mn-by-2026-Owing-to-High-Diagnostic-Accuracy-TMR.html 

Sinus Dilation Devices Market  -

https://www.globenewswire.com/news-release/2019/02/22/1740326/0/en/Sinus-Dilation-Devices-Market-to-be-worth-US-4-074-6-million-by-2026-TMR.html

0 votes

Transparency Market Research (TMR) has published a new report on the systemic lupus erythematosus treatment market for the forecast period of 2019–2027. According to the report, the global systemic lupus erythematosus treatment market was valued at ~US$ 1.7 Bn in 2018, and is projected to expand at a CAGR of ~7% from 2019 to 2027.

Systemic Lupus Erythematosus Treatment Market: Overview

  • Growth of the global systemic lupus erythematosus treatment market can be attributed to rise in the incidence of systemic lupus erythematosus, and promising drug pipeline and approvals.
  • North America dominated the global systemic lupus erythematosus treatment market in 2018, and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early new product adoption, and the presence of major market players are expected to drive the market in North America.
  • Asia Pacific is expected to be a highly lucrative market for systemic lupus erythematosus treatment, expanding at a high CAGR during the forecast period.

Immunosuppressive Drugs to Dominate Market

  • Based on drug, the global systemic lupus erythematosus treatment market has been divided into antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, immunosuppressive drugs, and others (biologics, B-cell modulators, etc.).
  • The immunosuppressive drugs segment dominated the global systemic lupus erythematosus treatment market in 2018, and the trend is likely to continue during the forecast period.
  • Immunosuppressive drugs such as azathioprine, cyclophosphamide, and methotrexate help control inflammation and the overactive immune system in the treatment of SLE. Furthermore, increase in the popularity of methotrexate as a treatment option is likely to boost the growth of this segment.
  • The immunosuppressive drugs segment can be further segmented into azathioprine, cyclophosphamide, methotrexate, and others. In terms of immunosuppressive drugs, the azathioprine sub-segment is anticipated to dominate the market.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73932

Oral Mode of Delivery to be Popular

  • In terms of mode of delivery, the global systemic lupus erythematosus treatment market can be divided into intravenous, subcutaneous, and oral.
  • The oral segment dominated the global systemic lupus erythematosus treatment market, due to an increase in the preference for self-administration of drugs such as immunosuppressive drugs, antimalarial drugs, and corticosteroids. This, in turn, is projected to drive the segment during the forecast period.
  • Furthermore, major market players are focusing on the launching of new products in the tablet and capsule form. This is likely to boost the growth of the segment during the forecast period.
  • The intravenous segment is expected to be a highly lucrative segment of the market during the forecast period. The intravenous route helps in the immediate delivery of drug, and since the delivery is into a vein, the drug starts working immediately. Moreover, drug degradation is less as compared to the oral route of administration.

Retail Pharmacies Accounted for Major Share of Market

  • Based on distribution channel, the global systemic lupus erythematosus treatment market has been segmented into hospital pharmacies, retail pharmacies, and online sales.
  • The retail pharmacies segment dominated the global systemic lupus erythematosus treatment market in terms of revenue in 2018, and the trend is projected to continue during the forecast period. Increase in the number of retail pharmacy stores across the globe, availability of new products in retail stores, and availability of most of the drugs, such as NSAIDS, antimalarial drugs, and corticosteroids, as OTC drugs in retail stores, are likely to propel this segment during the forecast period.
  • Hospital pharmacies is expected to be the second-most lucrative segment of the global systemic lupus erythematosus treatment market during the forecast period. The segment is expected to expand at a significant CAGR from 2019 to 2027,due to an increase in the demand for recently launched new products for systemic lupus erythematosus treatment.

North America to Dominate Global Market

  • In terms of region, the global systemic lupus erythematosus treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global systemic lupus erythematosus treatment market in 2018, followed by Europe.
  • North America accounted for a major share of the global systemic lupus erythematosus treatment market in 2018, owing to an increase in the use of systemic lupus erythematosus treatment products, especially for various symptoms of the disease. Additionally, the launch of new products by major pharmaceutical manufacturers fuels the market in this region.
  • The systemic lupus erythematosus treatment market in Asia Pacific is likely to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in the prevalence of systemic lupus erythematosus, improving healthcare infrastructure in terms of better facilities, and rise in the demand for advanced products. According to a latest study, the prevalence was in the range of 4.3 to 45.3/100,000 person per year.

Systemic Lupus Erythematosus Treatment Market: Competitive Landscape

  • The global systemic lupus erythematosus treatment market is fragmented in terms of number of players.
  • Key players operating in the global market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Company, Anthera Pharmaceuticals, Inc., ImmuPharma PLC, and Aurinia Pharmaceuticals, Inc.

More Trending Reports by Transparency Market Research –

Hearing Aids Market: prnewswire.com/news-releases/hearing-aids-market-increasing-prevalence-of-hearing-loss-worldwide-augments-product-demand-says-tmr-300857268.html

Viral Vector and Plasmid DNA Manufacturing Market: globenewswire.com/news-release/2019/04/30/1812834/0/en/Viral-Vector-and-Plasmid-DNA-Manufacturing-Market-is-anticipated-to-surpass-US-2-Billion-by-2027-TMR.html

...